Articles Tagged With:
-
Nipocalimab-aahu Injection (Imaavy)
The U.S. Food and Drug Administration has approved a neonatal Fc-receptor (FcRn) blocker for the treatment of generalized myasthenia gravis. Nipocalimab-aahu is a recombinant human immunoglobulin G1 lambda monoclonal antibody directed at FcRn with high affinity and selectivity.
-
TIA Is Associated with Accelerated Cognitive Decline
The study investigators looked at data from a prospective study of 30,239 Black and white community-dwelling persons aged 45 years or older with cognitive evaluations over the phone every other year until 2022. The researchers documented patients who had transient ischemic attack (TIA) or stroke, and demonstrated that persons who had TIA had a cognitive decline trajectory similar to those patients who had a definite diagnosis of stroke.
-
Looking Beyond LDL in Cardiovascular Risk Screening for Women
In a 30-year prospective study of nearly 28,000 initially healthy U.S. women, baseline levels of high-sensitivity C-reactive protein, low-density lipoprotein cholesterol or lipoprotein(a) independently and additively predicted major cardiovascular events.
-
Measles Outbreaks in the United States
Several measles outbreaks have been active in the United States, with more than 1,000 cases reported already in 2025. Most outbreaks begin as unvaccinated individuals in the United States come into contact with an infected individual who has recently arrived after international travel. Vaccination is effective, but current U.S. vaccine coverage rates are below the 95% rate considered necessary to provide herd immunity.
-
Community Engagement Can Help Prevent Unintended Teenage Pregnancies
Various studies show that comprehensive sex education for youth can reduce unintended teen pregnancies.
-
Abortion Restrictions Lead to Worse Outcomes in Maternal Health, Poverty, and More
Researchers found that state laws that more severely restricted abortion access in the time period of 2011-2019 were associated with worse maternal health outcomes for the most vulnerable women.
-
What Hormonal Side Effects Should New Users of the Levonorgestrel 52-mg IUD Expect?
This secondary analysis compares the incidence of hormone-related side effects of the levonorgestrel 52-mg intrauterine device (IUD) between users who previously were using combined hormone contraceptives vs. nonhormonal contraceptives to understand which side effects can be directly attributed to the IUD and which are more likely secondary to discontinuation of combined hormonal contraceptives.
-
Research Examines Which Patients Discontinue IUDs in Pre- and Post-Dobbs Eras
Intrauterine devices have become more popular in the United States. Researchers have found that intrauterine device removals also have changed since Dobbs, with removals decreasing significantly between the time periods 2017-2019 and 2022-2023.
-
Update on Early Pregnancy Loss Management
Early pregnancy loss affects 15% to 20% of pregnancies and typically is diagnosed via ultrasound. Management options — expectant, medical, or procedural — should be tailored to patient preference. For medical management, mifepristone combined with misoprostol offers the highest success. Routine Rh testing before 12 weeks is no longer broadly recommended. Shared decision-making and access to effective medications remain critical.
-
Which Method Is Best for Assessing Fetal Well-Being During Labor?
Although this study began as a randomized controlled trial and did not show a statistically significant difference between groups for the primary outcome, pooled analysis via a meta-analysis incorporating prior pilot data suggested a potential reduction in cesarean delivery with digital fetal scalp stimulation (dFSS) compared to fetal scalp blood sampling. Secondary maternal and neonatal outcomes were similar between the two groups, both procedures were well-tolerated, and clinicians showed a clear preference for dFSS.